EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Nyse  -  05/20 04:00:02 pm EDT
94.32 USD   -0.05%
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/17Citigroup Adjusts Price Target on Edwards Lifesciences to $115 From $134, Reiterates Buy Rating
MT
05/16Edwards announces key events for europcr 2022
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
95.93(c) 97.39(c) 93.41(c) 94.37(c) 94.32 Last
2 385 156 2 269 599 2 155 679 2 407 047 2 956 632 Volume
-1.66% +1.52% -4.09% +1.03% -0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 5 734 M - -
Net income 2022 1 558 M - -
Net cash position 2022 1 316 M - -
P/E ratio 2022 38,2x
Yield 2022 -
Sales 2023 6 412 M - -
Net income 2023 1 724 M - -
Net cash position 2023 2 470 M - -
P/E ratio 2023 34,6x
Yield 2023 -
Capitalization 58 675 M 58 675 M -
EV / Sales 2022 10,0x
EV / Sales 2023 8,77x
Nbr of Employees 15 700
Free-Float 96,5%
More Financials
Company
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - hemodynamic monitoring systems (67%); - heart valves and surgery products (17%); - other (16%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United... 
More about the company
Ratings of Edwards Lifesciences Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EDWARDS LIFESCIENCES CORPORATION
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/17Citigroup Adjusts Price Target on Edwards Lifesciences to $115 From $134, Reiterates Bu..
MT
05/16Edwards announces key events for europcr 2022
PR
05/11INSIDER SELL : Edwards Lifesciences
MT
05/04EDWARDS LIFESCIENCES CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
04/29INSIDER SELL : Edwards Lifesciences
MT
04/28EDWARDS LIFESCIENCES CORP Management's Discussion and Analysis of Financial Condition ..
AQ
04/28TRANCHE UPDATE ON EDWARDS LIFESCIENC : EW)'s Equity Buyback Plan announced on May 5, 2021.
CI
04/28TRANCHE UPDATE ON EDWARDS LIFESCIENC : EW)'s Equity Buyback Plan announced on May 8, 2019.
CI
04/27Canaccord Genuity Adjusts Edwards Lifesciences' Price Target to $137 from $152, Keeps B..
MT
04/27Raymond James Adjusts Edwards Lifesciences' Price Target to $124 from $126, Keeps Outpe..
MT
04/27Goldman Sachs Adjusts Price Target for Edwards Lifesciences to $105 From $102, Maintain..
MT
04/27RBC Cuts Price Target on Edwards Lifesciences to $135 From $142, Maintains Outperform R..
MT
04/27SVB Leerink Adjusts Price Target on Edwards Lifesciences to $138 From $145, Keeps Outpe..
MT
04/26EDWARDS LIFESCIENCES : REPORTS FIRST QUARTER RESULTS - Form 8-K
PU
More news
News in other languages on EDWARDS LIFESCIENCES CORPORATION
05/11VENTE PAR DES INITIÉS : Edwards Lifesciences
04/29VENTE PAR DES INITIÉS : Edwards Lifesciences
04/26Le bénéfice du premier trimestre d'Edwards Lifesciences augmente grâce à la hausse des ..
04/26Edwards Lifesciences Corporation annonce ses résultats pour le premier trimestre clos l..
04/26Earnings Flash (EW) EDWARDS LIFESCIENCES CORPORATION affiche un revenu de 1,34 milliard..
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 94,37 $
Average target price 125,90 $
Spread / Average Target 33,4%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EDWARDS LIFESCIENCES CORPORATION-27.16%58 675
THERMO FISHER SCIENTIFIC-18.74%215 594
DANAHER CORPORATION-24.22%178 480
INTUITIVE SURGICAL, INC.-39.29%78 303
SIEMENS HEALTHINEERS AG-17.17%64 740
BOSTON SCIENTIFIC CORPORATION-7.04%56 454